NanoImaging Services, Inc., the premier industry provider of cryoEM services, microscope access and training, and Viva Biotech Holdings, a leading open-access and innovation-driven technology platform company, have announced a partnership agreement to develop a streamlined, cryoEM enabled gene-to-structure workflow, to ultimately accelerate medicinal chemistry analysis.

This strategic partnership will bring together NanoImaging Services’ industry-leading expertise and innovation in high-resolution structural enablement by cryoEM and Viva Biotech’s world leading drug discovery platform to enable the management of projects from construct design through to final maps and subsequent protein supply, and analyses for medicinal chemistry cycles. This seamlessly integrated workflow will facilitate target and structure validation for companies with challenging targets in an efficient and cost-effective manner, streamlining drug discovery pipelines and ultimately reducing the time to clinic.

Giovanna Scapin, Ph.D., Chief Scientific Officer at NanoImaging Services said, “One of the strongest predictors of success in structural enablement of drug discovery targets is the purity, homogeneity, and in-depth biochemical and biophysical characterization of the reagents involved. This agreement utilizes our industry-leading expertise and innovation in high-resolution structural enablement by cryoEM, partnered with a worldwide leader in protein production and characterization. Together we aim to successfully target the most complex and challenging projects in drug discovery for our shared clients in a cost- and time- effective manner.”

“We are very excited to build the strategic cooperation with NanoImaging Services,” said Dr. Ren Delin, Executive Director and President of Viva. “NanoImaging Services, the world's top cryoEM service provider, has considerable advantages in technology and equipment. As the world's leading drug discovery platform, Viva has efficient protein purification and production capabilities, along with the advanced membrane protein expression and screening technology. Our cooperation is expected to further enhance the ability of target discovery, to empower the clients to develop new drugs as soon as possible, and benefit more patients.” said Dr. Ren Delin, Executive Director and President of Viva Biotech.

By combining forces and aligning these already successful and proven workflows, target enablement and medicinal chemistry timelines can be shortened significantly. This, along with the increased success rates, can contribute to bringing down the overall investment costs and creating a more efficient workflow.

To find out more about NanoImaging Services cryoEM solutions for protein structure determination, please visit our website here.

About NanoImaging Services
NanoImaging Services, Inc. launched in 2007 to provide imaging services to the pharmaceutical, biotechnology and nanotechnology communities. We have since built a client-focused organization with a reputation for expertise, reliability and collaboration. NIS is committed to expanding our service capacity through microscope acquisition, workflow automation, recruitment and training of top talent, and development of new service offerings. Our state-of-the-art facilities include a range of electron microscopes, sample preparation equipment and computational infrastructure to support structural biology, nanoparticle characterization and chemistry workflows. With recent acquisitions, NIS has become the largest and most comprehensive provider of TEM, cryoEM and microED services to the industrial life science market. For more information, visit: www.nanoimagingservices.com.

About Viva Biotech Holdings
Since its establishment in 2008, Viva Biotech (01873.HK) has always been adhering to the mission of "Becoming the cradle of global innovative biotech companies from around the world" and provided one-stop services for drug R&D and production to global biopharmaceutical innovators. Leveraging the technical advantages in the field of Structure-based Drug Discovery (SBDD), we provide leading CRO drug discovery services and CMC / CDMO services throughout the whole drug production process to global biopharmaceutical clients. At the same time, we focus on finding and investing in high potential biotech start-ups, solve unmet clinical medical needs in the form of EFS (service for equity), and continue to build an open cooperation platform and win-win ecosystem for biotech innovation.

As of June 30, 2021, Viva Biotech has provided drug R&D and production services to 1,695 biotech and pharmaceutical clients around the world. We have invested and incubated 75 biotech start-ups in total. In the future, the Company will continue to strengthen its technical barriers, improve R&D and production level, and the service capacity, so as to provide high-quality and diversified services for more drug discovery start-ups, as well as the medium and large pharmaceutical enterprises around the world. We hope to benefit more patients through Viva’s platform.